Article Text
Abstract
Introduction/Background*The objective of this study was to investigate the safety and treatment efficacy of J-Plasma in cases of advanced Epithelial Ovarian Cancer with upper abdominal involvement undergoing peritoneal and diaphragmatic stripping.
Methodology A retrospective review of a prospectively maintained database of patients who had diaphragmatic stripping with the use of J-Plasma ® from January 2016 to September 2019, due to peritoneal dissemination for advanced stage ovarian cancer (FIGO stage ≥III) was performed.
Result(s)*A total of 12 patients who underwent diaphragmatic stripping with the use of J-plasma for cytoreduction due to advanced ovarian cancer were included. Baseline patients characteristics are shown at table 1. The type of surgical procedure, median operative time, median estimated blood loss, time for the diaphragmatic resection, median length of hospital stay and postoperative complications are shown at table 2. No major intraoperative complications were recorded including J-plasma related. No defect in the diaphragmatic integrity and connection with the pleural cavity following resection were detected as evaluated by the “bubble test”. During a median follow-up period of 12 months (range:6-26 months), 2 patients (17%) presented with a disease recurrence (one local pelvic wall recurrence and one distant peritoneal) while none of the patients died of the disease during the follow-up period. Median disease free survival was 12 months (range:10-13 months)
Conclusion*J-plasma can be used during diaphragmatic stripping as it is associated with low rates of short-term morbidity and less operative time needed for stripping which are lower compared to the one that follows traditional peritoneal technic. Furthermore, in terms of disease control it seems to be particularly effective as none of patients experienced disease relapse in abdominal regions that were treated with J-plasma.